Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625052 | 1.00 | HTT (0.54) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL29625044 | 0.88 | MAPT (0.52) | MEN1KMT2ATP53LMNASMN1; SMN2 | |
| SCHEMBL20209486 | 0.88 | MAPT (0.52) | MEN1KMT2ATP53LMNASMN1; SMN2 | |
| SCHEMBL31666071 | 0.83 | DRD5 (0.38) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL20209215 | 0.83 | DRD5 (0.38) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL2015349 | 0.82 | HTT (0.57) | HTTMEN1KMT2ATP53LMNA | |
| Formic Acid SCHEMBL21460840 | 0.79 | DRD5 (0.35) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL21460659 | 0.75 | CD38 (0.39) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL31666053 | 0.75 | CD38 (0.39) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL2018696 | 0.75 | MEN1 (0.65) | HTTMEN1KMT2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2025-07-29 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| WO-2018096325-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | HTT 3173/4885MEN1 2895/4885KMT2A 4337/4885 |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | NHERF1, SCNN1B, SCNN1A | HTT 3185/4885MEN1 2646/4885KMT2A 4508/4885 |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | HTT 3173/4885MEN1 2895/4885KMT2A 4337/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | HTT 3185/4885MEN1 2646/4885KMT2A 4508/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | HTT 3185/4885MEN1 2646/4885KMT2A 4508/4885 |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | HTT 3173/4885MEN1 2895/4885KMT2A 4337/4885 |
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | HTT 3185/4885MEN1 2646/4885KMT2A 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.